CEO Message

NEORNAT Inc. is a specialized RNA anti-cancer therapeutics developing company that discovers first-in-class targets through RNA functional research and in vitro & in vivo verification studies, and conducts clinical development with NEORNAT's own RNA treatment strategies.

For a long time, RNA has been attracting attention only for its role in transcribing proteins based on genomic DNA sequences, but recently, it has been reported that numerous non-coding RNAs have a pivotal roles on the transcription and translation of functional genes in cells. NEORNAT aims to become a leading company in the development of RNA therapeutics that selectively target RNA or RNA regulatory factors contributing diseases, particularly cancer, with high-level research as the source technology. The main pipelines are first-in-class RNA targets including macrophage immune-checkpoint inhibitor, oncogenic super enhancer, long non-coding RNA (lncRNAs), and DNA repair enzymes. In addition, NEORNAT discovered multiple biomarkers for early diagnosis of liver cancer for the first time in the world, and raised the diagnostic accuracy to 100% level by utilizing multi-marker analysis. In the future, a new liver cancer diagnosis kit that can accurately diagnose early liver cancer at the pre-cancerous stage level will be developed through clinical verification experiments.

With these efforts and achievements, NEORNAT Inc. promises to contribute to human health and quality of life.

NEORNAT Inc. CEO
prof. Suk Woo Nam. PhD
swnam@neornat.com

Company Identity

NEORNAT Inc. develops first-in-class anti-cancer RNA drugs targeting functional RNAs and their specific regulators in cancer.

NEORNAT

=

Neo (The New)

+

RNA + T (Therapy)

The New RNA Therapeutics Company
First-in-Class Target Therapeutics

RNA Therapeutics

*Source: Globaldata, Published image from KoData

The need for RNA therapy

As a next-generation genetic drug, sufficient potential has been verified through the COVID-19 vaccine.
Normalizes intracellular pathological mechanisms that are difficult to target with existing drugs.
With the development of RNA stability and delivery technology, many obstacles for the development of RNA therapeutics are being resolved.

Advantages of RNA Therapeutics

It fundamentally cures diseases by blocking disease-expressing genes.
As a substance originally present in the body, it is not toxic by itself, and unlike DNA therapy, it does not affect the host genome, so there is little concern about safety.
The production process is relatively simple and inexpensive.

*Source : Research and markets, Precedence research data reprocessing

Rapid growth of the RNA therapeutics market

The global market is showing high growth every year as siRNA treatment was approved by the FDA in 2018.
As a first-in-class new drug, active technology export is possible even in the early stages of development.

History

2024

06
06
05
05
05
04
03
01

2023

12
NEORNAT, Co., Ltd. completes investment attraction from Korea Technology Finance Corporation
12
NEORNAT Co., Ltd. signed an agreement with Liberi Group, a global consulting company, to transfer overseas technology and promote multinational joint development of NEORNAT's major assets.
11
Visit and inspection of WuxiAppTech, Neona Co., Ltd.’s IND carrying out CDMO agency
07
Signed a joint R&D agreement with Neona Co., Ltd. and Ceratgen Co., Ltd. for 'RNA-based liver cancer immunotherapy'
05
[Korea Angel Investment Association] Selected as a TIPS startup commercialization support project (US$ 80,000)
04
NEORNAT Co., Ltd. presents NRT-YHD_001 pipeline non-clinical results at the 2023 AACR at Florida, Olando, USA
04
National New Drug Development Agency, KDDF] New drug development project (non-clinical development part) final selection (support size, US$1.6 million ( / 2 years)
Macrophage activity-based liver cancer RNA immunotherapy NRT-YHD_001 IND Package completion and approval goal
02
Signed a business agreement for IND approval of RNA-based anti-cancer drug NRT-YHD_001 with AIMSBiosciences Co., Ltd.

2022

11
Selected as Korea Angel Investment TIPS
09
Established NEORNAT affiliated R&D Center (2F, 47-3, Banpo-daero 39-gil, Seocho-gu, seoul, 06579 Korea )
06
Steintech Bio Season 1, Final Round Top 5 Selection and Best Company Selection
03
Completed pre-round Series A investment
02
Signed an MOU with Labgenomic for research and development of RNA-based anti-cancer drugs

2021

12
Catholic University Industry-University Cooperation Foundation- NEORNAT Inc. transfers 3 technologies for new drug development
12
NEORAT - AlgokBio signed an agreement to be the preferred bidder for liver cancer drug development
07
Selected as Korea Angel Investment TIPS
04
Selected as a 3-year project for the disease-centered translational research project
01
Shinhan Capital Investment Attraction

2020

11
Catholic University Industry-University Cooperation Foundation - Completed technology transfer for 4 cases of NEORNAT Inc.
10
Selected as K-BIC STAR (New drug development start-up company, Korea Health Industry Promotion Agency)
09
Completed attracting angel investment
Established NEORNAT Inc.

People

Founder, CEO & CTO Suk Woo Nam

Professor, Department of Pathology, College of Medicine, The Catholic University of Korea (present)
Director of Functional Rnomics Research Center, Catholic University of Korea (present)
President, Basic Professors Association of College of Medicine, The Catholic University of Korea (Present)

Sungkyunkwan University Department of Pharmacy, Master of Pharmacy, Doctor of Pharmacy
Post-doctoral Fellow, Lab of Pathology, NCI, NIH, USA
Senior Scientist, Genome Institute of Singapore, Singapore

Published more than 254 SCI papers, and 28 patent applications and registrations
Korea National Academy of Medicine Award for Basic Medicine (Pfizer Medical Award), 2014
Minister of Health and Welfare Award, 2015
Minister of Environment Award, 2013
Served as a judge for the Ho-Am Award for Medicine
Served as a judge for KOSDAQ technology special listing (RNA new drug part)

Head of NEORNAT Regulatory Science Chang Won Park, Ph.D.

Pharmaceutical Regulatory Science General Manager
Ph.D. in Pharmacy, Department of Pharmacy, Sungkyunkwan University, Korea.

Former Health Researcher at the Ministry of Food and Drug Safety
Experience in various departments including General Toxicology, Neurotoxicology, Organ System Drugs, Antibiotic and Anticancer Drugs, Drug Approval Review Coordination, Hazardous Substance Analysis, Cosmetic Research, Oncology Drugs, Pharmacology Research, Cardiovascular and Imaging Devices, and Medical Device Research.

Recipient of the Prime Minister's Commendation from the Ministry of the Interior and Safety, 2009.
Expert in Non-clinical Drug Testing (Toxicology Testing)
Expert in the Safety/Efficacy Evaluation of Drugs and Medical Devices

Head of Nonclinical Development Sang Yean Kim

Team leader : non-clinical development of new drug candidates department (current)

Ph.D., College of Medicine, The Catholic University of Korea
Major in Tumor Biology
Major in RNA Cancer Biology
Major in Targeted-RNA therapy Development

7 SCI articles including Oncogene and 3 patent applications
Modified mouse lung cancer analysis expert
Responsible for the development of Macrophage RNA Immunotherapy
Responsible for research and development of siRNA mix therapeutics
Responsible for GLP-Tox and PK/PD assessment

Head of active and lead material development Min Jeong Na

Team leader: new drug effective and leading substance development & verification department (current)

Ph.D., College of Medicine, The Catholic University of Korea
Major in Tumor Biology
Major in DNA Repair & Cancer Biology
Major in RNA Variation & Cancer

4 SCI articles including Experimental Molecular Medicine and 3 patent applications
Real-time mouse liver cancer image analysis expert
Responsible for the development of novel DNA repair enzyme-targeted therapy
Responsible for non-clinical efficacy evaluation

Head of early cancer diagnosis development Jung Hwan Yoon

Team leader: digestive cancer RNA drug development (current)

Ph.D., College of Medicine, The Catholic University of Korea
Major in Tumor Biology
Experience in the early diagnosis and development of gastric cancer

50 SCI articles including Cancer Commun and 13 patent applications
Gastric cancer early diagnosis kit development expert
Specialist in the development of anticancer drugs targeting gastric cancer carcinogenesis
Head of gastric cancer drug effective and lead material development and verification research